Amgen’s cheaper version of AbbVie’s top-selling arthritis drug Humira (adalimumab) is highly similar in efficacy and safety to the original and should be approved, an advisory panel to the FDA unanimously recommended. However, AbbVie is trying to block Amgen’s drug from reaching the market, claiming it has patents to protect Humira in the U.S. until at least 2022.

Click here for more.